Semax

This is where Semax differs from most peptides on Pepwyse: it is a registered medicine in Russia, approved by the Russian Ministry of Health since the 1990s under the brand name Semax (0.1% nasal drops for cognitive use; 1% drops for ischaemic stroke). It sits in roughly the same regulatory bucket as Selank, a real Russian-approved drug that does not exist as an approved medicine in any Western jurisdiction. The Russian and Western pharmacovigilance frameworks are not interchangeable, and a Russian registration is not the same as FDA/MHRA/EMA approval.

The Semax literature is real, but it is asymmetric. The peptide has been studied for over three decades, with a substantial body of mechanistic work, BDNF/TrkB upregulation, transcriptomic shifts in immune and vascular gene clusters after experimental stroke, effects on dopaminergic and serotoninergic signalling, and a track record of use in Russian clinical practice for ischaemic stroke and cognitive/anxiety indications. The Russian post-stroke trial by Gusev et al. (2018) is a genuine clinical study with a sensible biomarker rationale, reporting faster functional recovery and higher plasma BDNF with Semax. The honest qualifier is that almost all of this work comes from the Institute of Molecular Genetics of the Russian Academy of Sciences and a small circle of collaborators, mostly published in Russian or Russia-affiliated journals, and has not been replicated in large multicentre Western RCTs. The 2025 Br J Pharmacol paper from a Chinese group is one of the first prominent independent confirmations of a Semax mechanism outside that orbit. Honest position: better evidenced than most "research peptides," but a long way short of the standard required for Western drug approval.

There is no approved human dosing protocol outside Russia. The registered Russian product is a nasal solution dosed in microgram drops to each nostril, with different concentrations (0.1% and 1%) for cognitive and stroke-recovery use; published trials describe courses of several days repeated with breaks. The research-chemical material sold to Western buyers is not the same regulated product, and its purity and concentration are not subject to pharmaceutical-grade quality control. A qualified clinician should be consulted before considering any peptide.

In the Russian clinical record, Semax has a generally favourable short-term safety profile, most reported adverse events are mild and local (nasal irritation, transient mucosal effects) and the molecule is non-hormonal despite its ACTH origin. The qualifier is the same one that applies to its efficacy data: most of the safety evidence comes from the developing groups, and the long-term and large-population Western safety record simply does not exist. Theoretical concerns include unknown effects of chronic BDNF/dopaminergic modulation, interactions with psychiatric and stimulant medications, and the fact that research-chemical Semax sold online is not quality-controlled, purity, sterility and dose accuracy vary. People who are pregnant, breastfeeding, have psychiatric conditions, take other CNS-active drugs, or are immunocompromised should be especially cautious.